arrow
E

Elisabeth Bergen

assistance publique hopitaux paris (aphp)
H指数:15
被引数:1,072

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Circulating tumor DNA driving anti-EGFR rechallenge therapy in metastatic colorectal cancer: the RASINTRO prospective multicenter study

循环肿瘤DNA驱动抗EGFR再挑战疗法在转移性结直肠癌中的应用:RASINTRO前瞻性多中心研究

2025-09-010
PRE
Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort

先前或并发恶性肿瘤与胃癌患者总生存期之间缺乏关联:来自一项大型欧洲单中心队列的证据

2025-08-290
OAAI
Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients – A post-hoc analysis of the PETACC 8 trial

合并用药对早期结直肠癌患者复发、生存和化疗耐受性的影响——PETACC 8试验的事后分析

2025-07-120
OA
Ascites of patients with solid tumors shows distinct inflammatory patterns

实体肿瘤患者的腹水表现出独特的炎症模式

2025-05-080
OAAI
Efficacy and safety of the combination of encorafenib/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study
2024-09-014
OAAI
Immune cell distribution and DNA methylation signatures differ between tumor and stroma enriched compartment in pancreatic ductal adenocarcinoma
2024-09-011
OAAI
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases

曲妥珠单抗-deruxtecan治疗活动性脑转移的HER2-positive乳腺癌患者的II期TUXEDO-1试验的最终结果分析

2024-07-048
OAAI
FINAL OUTCOME ANALYSIS FROM THE PHASE II TUXEDO-1 TRIAL OF TRASTUZUMAB-DERUXTECAN IN HER2-POSITIVE BREAST CANCER PATIENTS WITH ACTIVE BRAIN METASTASES
2024-05-020
PRE
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma-a retrospective, international, multicentric AGEO study
2023-03-072
PRE
NEURON-SPECIFIC ENOLASE (NSE) AND S100 SERUM LEVELS IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HER2-POSITIVE BREAST CANCER TREATED WITH TRASTUZUMAB-DERUXTECAN (T-DXD): A BIOMARKER ANALYSIS FROM THE TUXEDO-1 TRIAL
2022-09-050
OA